

The small fiber neuropathy NaV1.7 I228M mutation: impaired neurite integrity *via* bioenergetic and mitotoxic mechanisms, and protection by dexamipexole

Seong-il Lee^{1,2}, Janneke G. J. Hoeijmakers³, Catharina. G. Faber³, Ingemar. S. J. Merkies^{3,4}, Giuseppe Lauria^{5,6}, and Stephen G. Waxman^{1,2*}

¹Department of Neurology, Yale University School of Medicine, New Haven, Connecticut

²Center for Neuroscience and Regeneration Research, Veterans Affairs Connecticut Healthcare System, West Haven, Connecticut

³Department of Neurology, School of Mental Health and Neuroscience, Maastricht University Medical Center+, Maastricht, the Netherlands

⁴Department of Neurology, St. Elisabeth Hospital, Willemstad, Curaçao

⁵Neuroalgology Unit Fondazione IRCCS Istituto Neurologico, "Carlo Besta" Milan, Italy

⁶Department of Biomedical and Clinical Sciences "Luigi Sacco", University of Milan, Milan, Italy

Corresponding Author*

Email address:

S-IL: seong.lee@yale.edu

JGJH: j.hoeijmakers@mumc.nl

CGF: c.faber@mumc.nl

ISJM: isjmerkies@hotmail.com

GL: Giuseppe.LauriaPinter@istituto-besta.it

SGW: stephen.waxman@yale.edu

30 Abstract

31 Gain-of-function variants in voltage-gated sodium channel NaV1.7 that increase
32 firing frequency and spontaneous firing of dorsal root ganglion (DRG) neurons have
33 recently been identified in 5-10% of patients with idiopathic small fiber neuropathy
34 (I-SFN). Our previous *in vitro* observations suggest that enhanced sodium channel
35 activity can contribute to a decrease in length of peripheral sensory axons.

36 We have hypothesized that sustained sodium influx due to the expression of SFN-
37 associated sodium channel variants may trigger an energetic deficit in neurons
38 which contributes to degeneration and loss of nerve fibers in SFN. Using an ATP
39 FRET biosensor, we now demonstrate reduced steady-state levels of ATP and
40 markedly faster ATP decay in response to membrane depolarization in cultured
41 DRG neurons expressing an SFN-associated variant NaV1.7, I228M, compared to WT
42 neurons. We also observed that I228M neurons show a significant reduction in
43 mitochondrial density and size, indicating dysfunctional mitochondria and a
44 reduced bioenergetic capacity. Finally, we report that exposure to dexamipexole,
45 a drug that improves mitochondrial energy metabolism, increases the neurite length
46 of I228M-expressing neurons.

47 Our data suggest that expression of gain-of-function variants of NaV1.7 can
48 damage mitochondria and compromise cellular capacity for ATP production. The
49 resulting bioenergetic crisis can consequently contribute to loss of axons in SFN. We
50 suggest that, besides interventions that reduce ionic disturbance caused by mutant
51 Nav1.7 channels, an alternative therapeutic strategy might target the bioenergetic
52 burden and mitochondrial damage that occur in SFN associated with Nav1.7 gain-of-
53 function mutations.

54

55 New and Noteworthy

56 Sodium channel NaV1.7 mutations that increase dorsal root ganglion (DRG) neuron
57 excitability have been identified in small-fiber neuropathy (SFN). Here we
58 demonstrate reduced steady-state ATP levels, faster depolarization-evoked ATP
59 decay, and reduced mitochondrial density and size in cultured DRG neurons
60 expressing SFN-associated variant NaV1.7-I228M. Dexamipexole, which improves
61 mitochondrial energy metabolism, has a protective effect. Since gain-of-function
62 Nav1.7 variants can compromise bioenergetics, therapeutic strategies that target
63 bioenergetic burden and mitochondrial damage merit study in SFN.

64

65 Introduction

66 Small fiber neuropathy (SFN) is a painful condition that typically begins to manifest
67 symptoms such as pain and sensory loss in the extremities of the body and spreads
68 to other regions. It is associated with depletion of intraepidermal nerve fiber (IENF)

and damage of unmyelinated and thinly myelinated peripheral nerve fibers in epidermal and dermal layers of the skin. What causes the damage to these sensory nerve fibers and terminals in SFN is not well understood.

Major causes of SFN include *diabetes mellitus*, chemotherapy and viral infection (Kokotis et al. 2016; Polydefkis et al. 2002; Smith et al. 2001). No apparent cause for SFN can be identified in 24% to 93% of cases in published patient series, and these cases are termed idiopathic SFN (I-SFN) (Bednarik et al. 2009; de Greef et al. 2018; Devigili et al. 2008; Lacomis 2002). Recently, Faber *et al.*, demonstrated gain of function (GOF) variants in NaV1.7 in a subset of patients with idiopathic SFN (Faber et al. 2012). Electrophysiological assessment of these variant channels demonstrated that their altered biophysical properties render sensory neurons hyperexcitable, endowing them with a reduced threshold, increased firing frequency, and spontaneous firing of action potentials across a broad range of stimulus intensities, which can contribute to spontaneous pain (Faber et al. 2012; Han et al. 2012a; Han et al. 2012b; Hoeijmakers et al. 2012c). However, little is known about the molecular or cellular bases underlying axonal injury, and IENF depletion in I-SFN associated with GOF variants.

Our previous *in vitro* observations suggest that enhanced sodium channel activity can contribute to a decrease in length of peripheral sensory axons (Persson et al. 2013b). We previously also demonstrated that the activities of normal (wild-type) voltage-gated sodium channels can contribute to growth impairment and degeneration of DRG neurites under metabolically challenging conditions (Persson et al. 2013a). Persistent membrane depolarization and Na⁺ influx *via* voltage-gated sodium channels, reverse Na⁺/Ca⁺⁺ exchanger, and the consequent ionic disturbance require increased activity of Na⁺/K⁺ ATPases and Ca²⁺ ATPases to cope with abnormal Na⁺ influx and maintain ionic gradient across the membrane (Carafoli 1991; Marunaka 1988).

Mitochondria are a major ATP source in neurons and are essential for the maintenance of nerve fiber integrity (Pellerin et al. 1998; Tantama et al. 2013). Dysfunctional mitochondria have been associated with axonal degeneration in multiple neurodegenerative diseases (Persson et al. 2013a; Takeuchi et al. 2005). Mitochondrial energy metabolism is regulated by several feedback mechanisms to accommodate fluctuating energy demands that reflect dynamic neuronal activities. Increased [ADP]_i and calcium influx induced by neural activity stimulate mitochondrial oxidative phosphorylation (OXPHOS) to compensate the increased ATP consumption (Lark et al. 2016; Rueda et al. 2014). Although OXPHOS constitutes an efficient mechanism to cope with abrupt increase in energy demand in neurons, its excessive activity can negatively impact mitochondrial function and bioenergetics *via* sustained Ca²⁺ influx and ROS generation (Persson et al. 2016).

108 In this study, we tested the hypothesis that GOF variants in Nav1.7, which are
109 associated with loss of IENFs in I-SFN, may produce a bioenergetic deficit in sensory
110 neurons. To address this question, we employed a cell culture model, and evaluate
111 the effect of an SFN-associated variant Nav1.7, I228M, on neurite length and ATP
112 level in DRG neurons. This particular variant was chosen for study because it
113 previously has been characterized in detail both clinically (Faber et al. 2012) and in
114 terms of its effect on channel and DRG neuron function (Estacion et al. 2011), and
115 because expression of this variant within DRG neurons has a larger effect on neurite
116 integrity *in vitro* than other GOF Nav1.7 mutant channels that have been studied
117 (Persson et al. 2013b). We also examined the effect of the variant channel on
118 mitochondria. Finally, we examined whether a drug that improves mitochondrial
119 energy metabolism protects against the impairment of neurite length in I228M-
120 expressing neurons.

121

122 **Materials and Methods**

123

124 *Plasmids*

125 The human WT Nav1.7 insert (containing the adult exon 5, E5A, and Long loop1)
126 and the Nav1.7 variant with residue substitutions I228M have been previously
127 described (Estacion et al. 2011). Full-length inserts of clones were sequenced
128 (Howard Hughes Medical Institute/Keck Biotechnology Center at Yale University)
129 and analyzed using BLAST (National Library of Medicine) and Lasergene (DNASar,
130 Madison, WI).

131 ATeam1.03-nD/nA/pcDNA(ATeam), the plasmid encoding a FRET-based ATP
132 indicator, has been previously described (Imamura et al. 2009) and was purchased
133 from Addgene (Addgene #51958).

134 pLV-mito-DsRed, the plasmid encoding a RFP variant tagged with 61 aa targeting
135 sequences of the P1 isoform F1F0-ATP synthase (N terminal on insert) has been
136 previously described (Kitay et al. 2013) and purchased from Addgene (Addgene
137 #44386).

138

139 *Isolation and culturing of dorsal root ganglion (DRG) neurons*

140 DRG from deeply anesthetized (Ketamine/Xylazine, 80/5 mg/kg bw) C57BL/6
141 mice (6-8 weeks) were isolated and cultured as described previously (Estacion et al.
142 2011; Persson et al. 2013a). Briefly, dissected ganglia were placed in ice-cold
143 oxygenated complete saline solution (CSS), containing (in mM) 137 NaCl, 5.3 KCl, 1
144 MgCl₂, 25 sorbitol, 3 CaCl₂, 10 N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid
145 (HEPES), pH 7.2, then incubated for 20 minutes in 37°C CSS containing Collagenase
146 A (1.5mg/mL), and for 20 minutes in 37°C CSS containing Collagenase D (1.5 mg/mL)
147 and Papain (30 U/mL). Ganglia were then triturated in DRG media (DMEM/F12

148 containing 100 U/mL penicillin, 0.1 mg/mL streptomycin (Invitrogen, Carlsbad, CA)
149 and 10% fetal bovine serum (Sigma-Aldrich, St. Louis, MO)), 1.5 mg/mL bovine
150 serum albumin and 1.5 mg/mL trypsin inhibitor (Sigma). The cell pellet was
151 resuspended in DRG media.

152

153 *Transfection of DRG neurons*

154 The dissociated DRG neurons were transfected by electroporation with WT
155 Nav1.7 channels and Nav1.7 channel variant I228M along with RFP (channel:RFP
156 ratio 10:2), using Nucleofector II (program SCN6; Amaxa, Gaithersburg, MD), as
157 previously described. (Rolyan et al. 2016). WT and I228M neurons were always
158 prepared from the same animal. After isolating the cell suspension, it was split half
159 and half for WT and I228M transfection so that paired cultures, prepared by the
160 same operator on the same day from the same animal, could be compared head-to-
161 head. The transfected neurons were allowed to recover for 5 minutes at 37°C in 0.5
162 mL of Ca²⁺-free DMEM. The cell suspension was diluted with Neurobasal A media
163 containing 2% B27, 1% GlutaMax and 100U/ml Penicillin-Streptomycin (Thermo
164 Fisher Scientific) and 150 µL of the cell solution was placed on 15 mm circular poly-
165 L-lysine/laminin-coated coverslips and incubated at 37°C in 5% CO₂ for 30 min. 2ml
166 of the standard culture media (Neurobasal A containing 25mM glucose, 2% B27, 1%
167 GlutaMax and 100U/ml Penicillin-Streptomycin) was added and cells were
168 maintained at 37°C in a 5% CO₂ incubator. For glucose concentration experiments
169 (Figure 2), the standard culture media (25mM glucose) were replaced with 5.7 or
170 2.7mM glucose- containing Neurobasal A.

171

172 *Live-cell imaging; neurite outgrowth assay and mitochondrial morphology*

173 Live-cell imaging for neurite measurement was performed using a Nikon
174 Eclipse Ti microscope (Nikon USA, Melville, NY) equipped with an environmental
175 chamber (In Vivo Scientific, St Louis, MO) to maintain the cells in a humidified
176 atmosphere at 37 °C. TRITC filter sets were used to visualize RFP fluorescence, and
177 images were acquired using NIS-Elements (Nikon). For each coverslip, a large-field
178 montage image consisting of 7×7 field-of-view images was acquired using a
179 motorized stage and a 10X objective.

180 Live-cell imaging for neuritic mitochondria was performed using the same
181 microscope setup. For each condition, 40 images from 2 distinct cultures were
182 acquired using 100X objective and DIC and TRITC filter sets to create two layered
183 images: one including mito-DsRed puncta and one including neurite morphology.

184

185 *Quantification of neurite lengths*

186 For quantification of neurite lengths, large-field images containing ~50-100
187 neurons (acquired as described above) were thresholded based on RFP signal using

ImageJ (National Institutes of Health, Bethesda, MS, USA) (with restrictions on signal intensity, size, roundness etc.) to create two binarized layers: one including cell bodies and one including cell bodies as well as neurites. The transfection rate for Schwann cells was very low ($<0.01\%$) and the level of expression of RFP in these cells was low so that these cells were readily excluded by threshold setting. In addition, using roundness setting we were also able to exclude Schwann cells, whose cell bodies are fusiform. Using particle analysis and skeletonize plugins in ImageJ (National Institutes of Health, Bethesda, MS, USA), the total neurite length was calculated for each large-field image and divided by the number of neurons within the field. Thus, a measure of the average neurite length/neuron was acquired for each large-field image. For each condition, 11-34 large-field images were analyzed from 3-8 independent cultures, in each case comparing neurite length/neuron for I228M channel-transfected neurons with neurite length/neuron for WT channel-transfected neurons, cultured at the same time in parallel to insure identical conditions. Normalized data are presented as mean $\pm$ SEM where n = number of large-field images, and differences between conditions analyzed using Student's unpaired t-test, and $P<0.05$ was considered significant.

205

206 *Quantification of mitochondrial morphologies*

207 For quantification of neuritic mitochondrial morphologies, images containing 1
208 or 2 neurites with mito-DsRed expression (acquired as described above) were
209 thresholded based on DsRed signal using ImageJ. Using particle analysis plugin,
210 total number and size of DsRed puncta were measured from TRITC images. Using
211 line trace and measurement tools in imageJ, total neurite lengths were measured
212 from DIC images. For the mitochondrial density, the total number of DsRed puncta
213 were normalized by total length of neurites within the field. Normalized data are
214 presented as mean $\pm$ SEM, differences between conditions analyzed using Student's
215 unpaired t-test, and $P<0.05$ was considered significant.

216

217 *ATP imaging*

218 Somatic and intraneuritic ATP were assessed using a FRET-based ATP indicator,
219 which increases FRET signal upon binding ATP (Imamura et al. 2009; Pathak et al.
220 2015). Isolated DRG neurons were transfected with ATeam1.03-nD/nA/pcDNA
221 along with a plasmid encoding either WT or I228M mutant Nav1.7 and cultured in
222 PLL/laminin-treated glass bottom Petri dishes (MatTek). At 4–7 days after plating,
223 FRET images of the cultures were acquired in standard bath solution (SBS)
224 containing the following (in mM): 140 NaCl, 3 KCl, 1 MgCl₂, 1 CaCl₂, and 10 HEPES,
225 pH 7.3, at room temperature. Neuronal cultures were illuminated with 514-nm light
226 to localize the neurons that were expressing the probe co-transfected with mutant
227 I228M or WT Nav1.7 channels. Neuronal cell bodies identified from YFP signal were

selected for ATP imaging. Neurons with expression of ATP indicator were illuminated with 436 nm using a Nikon Ti-E inverted microscope equipped with a fast switching xenon light source (Lambda DG-4; Sutter Instruments). Dual emission ratio images were captured using a QuantEM CCD camera (Princeton Instruments) and 20X objective (Super Fluor; Nikon) with a DV2 beam splitter (Photometrics) and the following filter sets (Semrock, Rochester, NY); 438/24 - DM458 - 483/32 (CFP) or 542/27 (YFP). The microscope system was controlled with NIS-Elements (Nikon). Imaging data were analyzed using NIS-Elements AR (Nikon). After background correction, YFP/CFP emission ratio was calculated by dividing YFP intensity by CFP intensity for each cell. Normalized data are presented as mean $\pm$ SEM, differences between conditions analyzed using Student's unpaired t-test, and $P < 0.05$ was considered significant.

240

241 *Stimulation protocol for ATP imaging*

Neuronal culture dishes were microperfused at a constant flow rate using a computerized valve system (ValveLink 8.2; AutoMate Scientific). To measure [ATP]_i transients in activated neuronal cell bodies and neurites, membrane depolarization was induced by perfusion with high [K⁺] solution (SBS containing 50 mM KCl/90 mM NaCl). After recording basal level of [ATP] in SBS for 60 s, neurons were exposed to high [K⁺] solution. During the microperfusion, neurons were illuminated every 2 s with 492-nm light using a Nikon Ti-E inverted microscope equipped with a fast switching xenon light source (Lambda DG-4; Sutter Instruments). Time lapse Images were captured using a QuantEM CCD camera (Princeton Instruments) and 20 objective (Nikon) under the control of NIS-Elements (Nikon).

252

253 *The quantification of ATP imaging*

Acquired images were digitized and analyzed with NIS-Elements software (Nikon). Based on YFP signal, images were thresholded, and a binary mask created over YFP-positive neuronal cell bodies and neurites. A binary mask overlaying each neuronal cell body was defined as a ROI. For neurites, each 50 μ m-long segment of the binary mask overlying the neurite was defined as the ROI. Fluorescence at 483-nm (CFP) and 542-nm excitation (YFP) mean pixel intensities were measured. After background correction, the ratio of YFP/CFP was calculated for each image. Mean values from neuronal cell bodies and neurites are depicted in graphs. The area under the curve (AUC) was calculated from t 60 s to t 180 s using Prism8 software (GraphPad). Differences between experimental groups were analyzed by Student's t-test, and $P < 0.05$ was considered significant.

265

266 *Statistics*

Statistical analysis was performed using Prism8 software (GraphPad), and either Students' t test or Mann–Whitney rank sum test was used. For neurite data sets, nested t test (Figure 1, 5, and 7), and nested one-way ANOVA (Figure 2) were used to accommodate cluster-related variation. Data are presented as mean ± standard deviation (SD). Mean difference ± SEM (MD) and 95% confidence intervals (CI) were also calculated to assess the magnitude of these differences. Statistical significance was accepted at $p \leq 0.05$ for all variables.

Effect size estimates for ATP FRET

FRET in Figure 3 is an arbitrary measurement for ATP levels. For more objective comparison of treatment effects in figure 3B and 3D, we standardized the effect sizes, using Cohen's d effect sizes (ES) with the resulting d values reported (Cohen 1988; Lenhard et al. 2016). We used an effect size calculator that considers standard deviation and sample number variation between groups as well as their non-parametric distributions (Lenhard et al. 2016; Fritz et al. 2012).

In this calculation, Cohen's d is computed from the equation;

$$d = \frac{2r}{\sqrt{1 - r^2}}$$

, where the point biserial correlation r is derived from U values from Mann-Whitney tests and sample sizes n of two groups, using Hans Wendt formula (Wendt, 1972),

$$r = \frac{1 - (2U)}{n_1 \times n_2}$$

Availability of data and materials

The datasets that support the findings of this study have been deposited in figshare at <https://figshare.com/s/5f02c47d446893384c34>.

Results

I228M, an SFN-associated Nav1.7 gain of function mutant, reduces the neurite length of cultured DRG neurons

Loss of intraepidermal nerve fibers (IENFs) is a hallmark of SFN and an important diagnostic criterion of the disease. We previously reported that GOF mutations in Nav1.7 are associated with I-SFN and showed that expression of these mutations renders sensory neurons hyperexcitable. In addition, following the expression of the GOF variants, dorsal root ganglion (DRG) neurons exhibit reduced neurite lengths (Persson et al. 2013b; Rolyan et al. 2016).

To establish an *in vitro* model for IENF loss by SFN-associated GOF variants in Nav1.7, we transfected DRG neurons with wild-type (WT) and variant I228M

NaV1.7 channels (co-transfected with red fluorescent protein [RFP] to enable the identification of transfected cells). As demonstrated in representative 49 field-of-view montage images (Figure 1A and C), cultures contained numerous RFP-positive neurons, 7 days after transfection, with robust RFP signal in cell bodies as well as neurites. Cell diameters varied between 20 μ m and 60 μ m. Examples of neurons transfected with WT and I228M are shown at increased magnification in Figure 1B and D.

Mean total neurite length/neuron was quantified from large-field images for WT- and I228M-transfected neurons. There was an 20% reduction ($p < 0.0001$) in length of neurites of I228M-expressing neurons as compared to those transfected with WT channels (Figure 1E). We did not differentiate between large and small diameter DRG neurons because neurites from each neuron made multiple crossings with neurites from adjacent neurons, making it impossible to locate the cell body (or cell body diameter) from which any given neurite arose.

DRG neurons expressing I228M exhibit decreased neurite length in low glucose concentration.

Neurite growth and/or the maintenance of neurite length *via* extension and regeneration is a high-energy demanding cellular process. Metabolically challenging conditions, especially associated with the shortage of ATP, prevent neurite extension and induce neurite degeneration (Chen et al. 2007; Estacion et al. 2015; Persson et al. 2016).

Glucose is a major substrate for ATP production and its availability affects cellular energetics (Tanaka et al. 2014; Tanaka et al. 2015; Tantama et al. 2013). We therefore examined how low glucose availability would affect neurite growth of cultured neurons. WT channel-expressing neurons exhibited similar neurite lengths in all three glucose concentrations (25, 5.7 and 2.7mM) with a trend of modestly increased neurite length in lower concentrations (Figure 2A). This result suggests that, in neurons that express normal (wild-type) voltage-gated sodium channels, neurite lengths are not strongly dependent on glucose availability in this model system, presumably because the channel activity and the resulting cellular activities are not a burden on neuronal bioenergetics.

In contrast to the WT cells, I228M neurons showed a trend toward markedly decreased neurite lengths at low glucose concentrations (5.7 and 2.7mM), compared to those in the control glucose condition (25mM) (Figure 2B). Average neurite length was reduced by 25% ($p=0.015$) in 2.5mM glucose, as compared to the control. Our results indicate that the presence of I228M channels imposes energetic burden on sensory fibers, rendering them more vulnerable to damage under conditions where the glucose level is low.

345 **DRG neurons expressing I228M exhibit a reduced steady-state level of ATP**

346 Impaired slow-inactivation of I228M is known to produce a sustained influx of
347 sodium, which would be predicted to lead to persistent activation of Na⁺/K⁺ ATPase
348 pumps (Estacion et al. 2015). The presence of I228M also produces increased
349 spontaneous firing of DRG neurons (Estacion et al. 2011). The firing of action
350 potentials induces synaptic vesicle cycling that imposes an additional energetic cost
351 (Pathak et al. 2015). We therefore expected that I228M-transfected neuron would
352 display low intracellular ATP level ([ATP]_i).

353 To address this question, we measured ATP levels in DRG neurons using a
354 genetically encoded FRET sensor, Ateam (Imamura et al. 2009). We transfected
355 DRG neurons with NaV1.7 wild type (WT) or I228M along with Ateam FRET sensor
356 and measured FRET (ratio between YFP emission/ CFP emission) signals from the
357 transfected cells 5-6 days after culturing. We compared FRET differences between
358 WT and I228M groups.

359 It is not clear if the relationship of FRET values and ATP levels is linear.
360 Recognizing this limitation, inferential statistical analysis was carried out using
361 Cohen's d effect sizes (Cohen 1988), which allows us to achieve standardized
362 comparison of treatment effect by NaV1.7 I228M (small effect = 0.20, medium
363 effect = 0.50 and large effect = 0.80). We calculated the effect sizes in the results of
364 Figure 3, using an effect size calculator that considers standard deviation and
365 sample number variation between groups as well as their non-parametric
366 distributions (Lenhard et al. 2016).

367 As shown in Figure 3A and B, I228M neurons displayed a modest reduction in
368 the FRET signal, compared to that of WT. Our test statistic ($p = 0.0042$) signifies this
369 reduction in the I228M. However, given the small effect size (Cohen's d = 0.315,
370 whether or not the effect size of this result is biologically meaningful remains to be
371 determined under the conditions that might permit changes of larger magnitude in
372 ATP level to occur.

373 Several feedback mechanisms might participate in the regulation of
374 mitochondrial ATP synthesis in these neurons. A moderate ATP reduction in I228M
375 neurons (Figure 3B) might be explained as a result of increased mitochondrial
376 metabolisms *via* feedback regulations (Estacion et al. 2015; Rolyan et al. 2016). We
377 therefore treated both WT and I228M DRG cultures with 1μM rotenone to inhibit
378 mitochondrial function and compared their steady-state levels of ATP. Rotenone
379 markedly reduced the FRET level in both WT and I228M cultures, indicating a
380 significant mitochondrial contribution to the FRET signal (Figure 3B and D).
381 However, in the presence of rotenone, I228M-transfected neurons showed a more
382 robust decrease in their FRET signal, compared to WT neurons. The average FRET
383 value of WT neurons shifted from 3.738 to 3.408 (9% reduction, Cohen's d = 0.315)
384 whereas the FRET signal in I228M cultures shifted from 3.542 to 3.031 (15%

reduction, Cohen's $d = 0.364$) (Figure 3B and D). This result suggests that I228M channels negatively impact neuronal bioenergetics *via* a reduction in $[ATP]_i$, for which mitochondria can partially compensate.

388

389 **DRG neurons expressing I228M exhibit a faster decay of $[ATP]_i$ in response to** 390 **membrane depolarization**

391 DRG neurons expressing I228M channels display an increased firing frequency
392 over a broad range of stimulus intensities even close to current threshold (Estacion
393 et al. 2011). We therefore asked how I228M expression influences the change of
394 $[ATP]_i$ in response to depolarization. We induced membrane depolarization in the
395 transfected DRG neurons *via* application of 50mM KCl and monitored the FRET
396 change of the ATP sensor in real-time.

397 As shown in figure 4, both WT- and I228M-transfected neurons displayed a
398 decrease in the FRET signal of ATeam in both cell bodies and neurites in response to
399 high K^+ application. However, the magnitude of the FRET reduction was greater in
400 I228M neurons than in WT neurons, suggesting that I228M neurons deplete their
401 $[ATP]_i$ more rapidly than that of WT. More rapid reductions of the FRET signal were
402 demonstrated in neurites than cell bodies (Figure 4B and D), possibly due to the
403 smaller diameter of neurites which are known to express a high level of sodium
404 channels (Black et al. 2012; Persson et al. 2010). Irrespective of the underlying
405 biophysical mechanism, the results indicate that neurites expressing I228M
406 channels are bioenergetically more vulnerable to energetic stress imposed by
407 depolarization than cell bodies, and that this vulnerability is markedly enhanced
408 under the expression of I228M channels.

409

410 **Pyruvate moderately increases neurite length in I228M neurons**

411 Cellular ATP is produced in part from the activities of glycolysis and
412 mitochondrial OXPHOS. Greater molar numbers of ATP are synthesized from
413 OXPHOS, utilizing pyruvate as a substrate (Figure 5A). Increasing pyruvate
414 availability has been demonstrated to facilitate mitochondrial ATP production and
415 prevent cell and tissue damage provoked by conditions that involve bioenergetic
416 stress (Geng et al. 2015; Izumi and Zorumski 2010; Peeling et al. 1996; So and Fuller
417 2003; Wang et al. 2018; Zeng et al. 2007).

418 We hypothesized that exogenous pyruvate might protect against the impairment
419 of neurite outgrowth in I228M-transfected neurons. To test this hypothesis, we
420 cultured I228M-expressing DRG neurons for 7 days in the absence and presence of
421 pyruvate and compared the neurite lengths under these conditions. In contrast to
422 this expectation, pyruvate treatment failed to significantly increase neurite length in
423 I228M neurons, despite a trend of slight increase (Figure 5B, left panel).

We initially reasoned that this result might reflect negative feedback regulation from glycolysis that would inactivate pyruvate dehydrogenase (Figure 5A). Because high glucose concentration in the culture condition is expected to strengthen the inhibition of pyruvate dehydrogenase (PDH) through PDH kinase (PDK) phosphorylation and prevent pyruvate from being incorporated into OXPHOS, we used dichloroacetate (DCA), a PKD inhibitor, to increase pyruvate flux into mitochondrial metabolism and evaluated its effect on neurite length of I228M neurons. However, DCA treatment was also ineffective in promoting neurite length of I228M neurons (Figure 5B, right panel).

I228M neurons display a marked reduction in the size and number of mitochondria.

We reasoned that the failure of the previous metabolic approaches might reflect alterations of mitochondria in I228M neurons. To address this possibility, we investigated the size and density of mitochondria, which are strongly associated with the functionality and bioenergetic capacity of the organelles (Youle and van der Blik 2012). We transfected DRG neurons with Mito-dsRED whose fluorescence is limited to mitochondria and assessed their morphologies and distribution in the transfected neurons. As shown in Figure 6, red fluorescence was expressed as puncta along the neurites, confirming the target specificity of Mito-DsRed (Kitay et al. 2013). In a comparison of WT and I228M cultures (Figure 6), I228M-expressing neurites exhibited significantly fewer DsRed puncta than WT-expressing ones. In addition, the size of DsRed puncta in I228M-neurites was significantly diminished, compared to that of WT neurites.

The extent of mitochondrial fusion and fission provide indices of the intactness of the subcellular organelle. Fragmented mitochondria, indicating increased fission, are in general associated with mitochondrial damage and reduced respiratory capacity (Rossignol et al. 2004; Westermann 2012). These results thus suggest that I228M expression leads to dysfunctional and degrading mitochondria, which is consistent with the ineffectiveness of pyruvate and DCA treatment in neurite length enhancement. They also suggest that mitochondrial alterations are at least in part involved in the reduced cellular energy state and neurite length in the mutant cells.

Dexpramipexole increases neurite length in I228M neurons.

Our results — short neurite length, impaired bioenergetics, and mitochondrial alterations in I228M neurons — predict that agents that protect or restore mitochondrial energy production might protect against the impairment of neurite length by GOF variants in NaV1.7.

An electrochemical gradient of protons is created by cellular respiratory activities of mitochondria. The ionic gradient across the inner mitochondrial

membrane is used to drive ATP synthesis. Maintaining the gradient is, therefore, critical to ensure sufficient ATP production *via* mitochondrial OXPHOS.

The mitochondrial permeability transition pore (mPTP) is known to regulate the ionic gradient in mitochondrial matrix. Despite its role in the regulation of mitochondrial Ca^{2+} level and metabolism, pathological conditions related to energetic stress and Ca^{2+} overload can cause prolonged opening of mPTP, and in turn induce mitochondrial dysfunction.

Dexpramipexole (DEX) blocks mPTP, enhances mitochondrial membrane potential and improves mitochondrial energy metabolism in models of neurodegeneration (Alavian et al. 2015; Alavian et al. 2012). To determine whether DEX protects against reduced neurite length of I228M neurons, we treated the neurons with this drug at a concentration previously reported to increase ATP levels in neuronal cultures (Alavian et al. 2012). As shown in Figure 7E, treated neurons displayed a significant increase in neurite length, compared to untreated group in parallel cultures. Mean total length/neuron was increased by 25% in DEX-treated I228M neurons. We also assessed the effect of DEX on WT neurons and found that 2 μM DEX did not alter neurite length of WT-transfected neurons (Figure 7F).

Those results indicate that mitochondrial mechanisms are indeed involved in the neuritic impairment of I228M neurons. They also suggest that a therapeutic strategy might target mitochondrial dysfunction to prevent IENF loss that occurs in DRG neurons carrying GOF mutations in NaV1.7.

Discussion

Gain-of-function mutations in NaV1.7 are related to loss of intraepidermal nerve fibers in I-SFN and reduce neurite lengths in cultured DRG neurons

The epidermis where IENFs reside is a dynamic terrain. The tissue continuously remodels itself. Because new keratinocytes arise at the base of the tissue, then migrate upwards and flatten preexisting keratinocytes, there is an ongoing change of intercellular space and extracellular matrix, which mandates IENFs to navigate through and adjust their ramification patterns while maintaining their skin innervation. IENFs achieve this goal by a dynamic process that involves repeated regeneration and degeneration (Cheng et al. 2010; Gibbons et al. 2010; Verze et al. 1999).

Previous skin biopsy studies have revealed that the density of nerve fibers innervating the epidermis is reduced, and some nerve fiber terminals display degenerating or retracting morphologies in the epidermis of SFN patients harboring GOF mutations in NaV1.7. Those observations suggest that the sensory nerve fibers

502 in SFN are “dying back” (Chai et al. 2005; Hoeijmakers et al. 2012b; Lauria et al.
503 2011).

504 The neurite outgrowth assay provides a simple *in vitro* method for assessment
505 of potential effects of genetic and exogenous factors on the integrity of the axons of
506 DRG neurons. (Filous and Silver 2016). In the present study, we chose the I228M
507 mutation of NaV1.7 because it has been characterized in detail both clinically (Faber
508 et al. 2012) and in terms of its effect on channel and DRG neuron function (Estacion
509 et al. 2011), and because expression of this variant within DRG neurons has a larger
510 effect on neurite integrity *in vitro* than other gain-of-function NaV1.7 mutant
511 channels that have been studied (Persson et al. 2013b). Using this *in vitro* assay,
512 DRG neurons transfected with I228M showed a reduced neurite length, compared to
513 WT channels (Figure 1).

514

515 **Gain-of-function mutations in NaV1.7 produce a bioenergetic deficit.**

516 Despite the statistical significance of our results in Figure 3, their small effect sizes
517 approximately equate to a 58.4-61.1% probability of superiority, suggesting that the effect
518 of I228M in this condition might be minimal at best (calculated from
519 <https://rpsychologist.com/d3/cohend/>). Whether or not a 0.3-0.4 standard deviation
520 difference between groups is biologically relevant remains to be determined through
521 further investigation. In SFN patients, neurodegeneration occurs in length-dependent and
522 age-dependent manners (Hoeijmakers et al. 2012a). Given this clinical feature of SFN,
523 culturing for longer periods of time, under conditions that permit growth of longer axons
524 and cumulative ATP reduction or mitotoxic effect, might permit changes of larger
525 magnitude in ATP level to occur.

526 I228M-expressing neurons demonstrated reduced levels of $[ATP]_i$ in the basal
527 state and increased ATP consumption rates in response to depolarization (Figure 3
528 and 4). These results suggest that decreased bioenergetic stores contribute to the
529 pathophysiology of SFN related to GOF variants of NaV1.7. Those mutations alter the
530 gating properties of the channels so that their pores open more frequently and/or
531 with longer duration (Estacion et al. 2011; Hoeijmakers et al. 2012c). Those
532 alterations expectedly increase Na^+ influx and, *via* reverse operation of Na^+/Ca^{++}
533 exchanger, alter $[Ca^{2+}]_i$ dynamics in neurons as demonstrated by the example of
534 G856D mutation (Estacion et al. 2015). To reverse the resulting ionic imbalance, the
535 excessive Na^+ and Ca^{2+} are necessarily pumped out, which requires increasing
536 activities of Na^+/K^+ -ATPase and Ca^{2+} -ATPase (Ames et al. 1992; Palmgren and
537 Nissen 2011; Sokoloff 1999). The increased activities of these pumps can impose an
538 energetic burden to neurons. In addition to that ionic disturbance, the variant
539 channels render neurons hyperexcitable with higher firing frequency and increased
540 spontaneous firing of action potentials that can confer an additional energetic
541 burden. (Estacion et al. 2011; Han et al. 2012a; Han et al. 2012b; Hoeijmakers et al.
542 2012a).

543

544 **Cellular energy state influences neurite length**

545 Multiple studies have suggested a link between bioenergetic state and the
546 maintenance of axonal integrity (Chowdhury et al. 2014; Estacion et al. 2015;
547 Persson et al. 2013a). Numerous cellular events take part in axon extension and
548 maintenance, including actin-microtubule reorganization, vesicle trafficking and
549 protein synthesis, and some of them are energetically demanding. It is thus not
550 surprising that impaired bioenergetic states have been shown to result in axonal
551 injury, growth inhibition and degeneration *in vitro* (Gibbons et al. 2010; Kitayama et
552 al. 2008; Natera-Naranjo et al. 2012; Persson et al. 2013a; Press and Milbrandt
553 2008). The continuous remodeling, that is required for IENFs *in vivo* to maintain
554 skin innervation as they accommodate to the addition of new epidermal cells and
555 their transit to the skin surface, may add to the energetic demand.

556 Our results suggest that a bioenergetic deficit contributes to the mechanism by
557 which GOF variants in NaV1.7 cause IENF loss. First, under the expression of I228M
558 mutant channels, DRG neurons displayed reduced steady-state levels of [ATP]_i and
559 rapid ATP consumption rates upon membrane depolarization. This result indicates
560 that the mutant channels impose bioenergetic stress on sensory neurons and their
561 nerve fibers. Second, neurite lengths in I228M neurons were markedly sensitive to
562 glucose availability, while this effect was not observed in WT cells. This result
563 suggests that the energetic burden by GOF variants in NaV1.7 renders nerve fibers
564 vulnerable to metabolic conditions that are benign to WT axons. Given that the low
565 glucose concentrations that we used fall within physiological ranges (Guemes et al.
566 2016), we suggest that the GOF variant channels trigger axonal damage at least in
567 part *via* a bioenergetic mechanism in I-SFN.

568

569 **Mitotoxicity and protection in peripheral sensory neuropathies**

570 The alterations of mitochondria in I228M neurons (Figure 6) indicate that
571 mitochondrial mechanisms also contribute to impaired bioenergetics and IENF
572 damage in I-SFN related to NaV1.7 mutations. Dysfunction and/or loss of
573 mitochondria have been recently suggested as a converging pathogenic mechanism
574 in multiple types of peripheral neuropathy (Bennett et al. 2014; Casanova-Molla et
575 al. 2012; Lehmann et al. 2011; Persson et al. 2016). DEX has been shown to have a
576 protective effect in several models of neurodegeneration (Alavian et al. 2015;
577 Alavian et al. 2012). The beneficial effect of DEX in our model system (Figure 7)
578 suggests the possibility that at least in the short term, a degree of therapeutic
579 protection of IENF may be achievable.

580

581 **Bioenergetic stress and pain**

Bioenergetic stress impairs the performance of Na⁺-K⁺-ATPase-dependent pump. This impairment contributes to a depolarizing shift in resting membrane potential, which can render neurons hyperexcitable prior to development of neuropathy (Nasu et al. 2014). Ischemic conditions are also known to result in bioenergetic deficits and increase membrane depolarization and axonal excitability (Han et al. 2008; Kiernan and Bostock 2000). Those results are consistent with our hypothesis and observations — GOF variants in Nav1.7 evoke bioenergetic stress, resulting in the impairment of the ATPases pumps and a disturbance of ionic gradient. We suggest that the ionic disturbance evoked by the variant channels and the consequent energetic burden may mutually amplify each other. The resulting positive feedback loop may, in the long term, aggravate spontaneous impulse generation and pain in SFN. For instance, increased ionic perturbation would decrease cellular energy. This energy crisis would consequently impair the function of the ATPase-dependent ion pumps. As a result, the residual ionic imbalance would be expected to persistently activate ATPases, further depriving cellular ATP. Through this cycling between ionic imbalance and bioenergetic stress, neurons would be increasingly depolarized and deprived of cellular energy. If affected neurons are nociceptors, this would contribute to an increased spontaneous pain. If such a cycling persists, the consequent severe bioenergetic crisis would lead to neurodegeneration of IENF.

Multiple GOF mutations of Nav1.7 have been linked to small fiber neuropathy (Faber et al. 2012; Han et al. 2012a; Han et al. 2012b). In previous studies, a subset of DRG neurons expressing the SFN G856D mutation demonstrated time-dependent neurite degeneration as well as neurite fragmentation under metabolically challenging conditions (Estacion et al. 2015; Rolyan et al. 2016). However, the G856D mutation produces a complex phenotype in which impaired distal limb development accompanies SFN (Hoeijmakers et al. 2012c). We speculate that many gain-of-function Nav1.7 mutations impose energetic stress on DRG neurons. Additional studies on other Nav1.7 mutant channels will be needed to confirm this proposal. Additional studies will be needed to determine whether bioenergetic or mitotoxic mechanisms contribute to the association that has been reported (Blesneac et al. 2018) between Nav1.7 mutations and painful diabetic neuropathy.

Conclusion

SFN is a progressive disorder and is often diagnosed when there is degeneration of nerve fibers. Our result suggests that, in addition to interventions that selectively reduce ionic imbalances caused by mutant Nav1.7 channels, an alternative therapeutic strategy might target the bioenergetic burden and mitochondrial dysfunction that occur in SFN associated with Nav1.7 gain-of-function mutations. Future studies will be needed to assess this approach with multiple SFN-associated

sodium channel mutations, and should aim at testing this mechanism *in vivo*, via the assessment of IENF and behavioral changes after interventions that protect bioenergetic mechanisms.

625

Acknowledgements

We thank Peng Zhao and Lawrence Macala for superb technical assistance and Monique M. Gerrits and Daria Sizova for helpful suggestions.

629

Competing interests

Dr. Faber reports grants from European Union's Horizon 2020 research and innovation programme Marie Skłodowska-Curie grant for PAIN-Net, Molecule-to-man pain network (grant no. 721841), grants from Prinses Beatrix Spierfonds, grants from Grifols and Lamepro for a trial on IVIg in small fibre neuropathy, other from Steering committees/advisory board for studies in small fibre neuropathy of Biogen/Convergence and Vertex, outside the submitted work.

Dr. Merkies reports Participation in steering committees of the Talecris ICE Study, CSL Behring, LFB, Novartis, Octapharma, Biotest and UCB, grants from Grifols and Lamepro for a trial on IVIg in small fibre neuropathy, outside the submitted work.

Dr. Hoeijmakers reports a grant from Prinses Beatrix Spierfonds, outside the submitted work. Dr. Waxman reports serving as an advisor or consultant to Amgen, Biogen, GlaxoSmithKline, Chromocell, and SiteOne Therapeutics.

644

References

Alavian KN, Dworetzky SI, Bonanni L, Zhang P, Sacchetti S, Li H, Signore AP, Smith PJ, Gribkoff VK, and Jonas EA. The mitochondrial complex V-associated large-conductance inner membrane current is regulated by cyclosporine and dexamipexole. *Mol Pharmacol* 87: 1-8, 2015.

Alavian KN, Dworetzky SI, Bonanni L, Zhang P, Sacchetti S, Mariggio MA, Onofrij M, Thomas A, Li H, Mangold JE, Signore AP, Demarco U, Demady DR, Nabili P, Lazrove E, Smith PJ, Gribkoff VK, and Jonas EA. Effects of dexamipexole on brain mitochondrial conductances and cellular bioenergetic efficiency. *Brain Res* 1446: 1-11, 2012.

Ames A, 3rd, Li YY, Heher EC, and Kimble CR. Energy metabolism of rabbit retina as related to function: high cost of Na⁺ transport. *J Neurosci* 12: 840-853, 1992.

Bednarik J, Vlckova-Moravcova E, Bursova S, Belobradkova J, Dusek L, and Sommer C. Etiology of small-fiber neuropathy. *J Peripher Nerv Syst* 14: 177-183, 2009.

Bennett GJ, Doyle T, and Salvemini D. Mitotoxicity in distal symmetrical sensory peripheral neuropathies. *Nat Rev Neurol* 10: 326-336, 2014.

Black JA, Frezel N, Dib-Hajj SD, and Waxman SG. Expression of Nav1.7 in DRG neurons extends from peripheral terminals in the skin to central preterminal branches and terminals in the dorsal horn. *Mol Pain* 8: 82, 2012.

663 **Blesneac I, Themistocleous AC, Fratter C, Conrad LJ, Ramirez JD, Cox JJ, Tesfaye S,**
664 **Shillo PR, Rice ASC, Tucker SJ, and Bennett DLH.** Rare Nav1.7 variants associated with
665 painful diabetic peripheral neuropathy. *Pain* 159: 469-480, 2018.

666 **Carafoli E.** Calcium pump of the plasma membrane. *Physiol Rev* 71: 129-153, 1991.

667 **Casanova-Molla J, Morales M, Garrabou G, Sola-Valls N, Soriano A, Calvo M, Grau JM,**
668 **and Valls-Sole J.** Mitochondrial loss indicates early axonal damage in small fiber
669 neuropathies. *J Peripher Nerv Syst* 17: 147-157, 2012.

670 **Chai J, Herrmann DN, Stanton M, Barbano RL, and Logigian EL.** Painful small-fiber
671 neuropathy in Sjogren syndrome. *Neurology* 65: 925-927, 2005.

672 **Chen W, Mi R, Haughey N, Oz M, and Hoke A.** Immortalization and characterization of a
673 nociceptive dorsal root ganglion sensory neuronal line. *J Peripher Nerv Syst* 12: 121-130,
674 2007.

675 **Cheng C, Guo GF, Martinez JA, Singh V, and Zochodne DW.** Dynamic plasticity of axons
676 within a cutaneous milieu. *J Neurosci* 30: 14735-14744, 2010.

677 **Chowdhury SR, Saleh A, Akude E, Smith DR, Morrow D, Tessler L, Calcutt NA, and**
678 **Fernyhough P.** Ciliary Neurotrophic Factor Reverses Aberrant Mitochondrial Bioenergetics
679 Through the JAK/STAT Pathway in Cultured Sensory Neurons Derived from Streptozotocin-
680 Induced Diabetic Rodents. *Cellular and Molecular Neurobiology* 34: 643-649, 2014.

681 **Cohen J .** Statistical Power Analysis for the Behavioral Sciences. 1988

682 **de Greef BTA, Hoeijmakers JGJ, Gorissen-Brouwers CML, Geerts M, Faber CG, and**
683 **Merkies ISJ.** Associated conditions in small fiber neuropathy - a large cohort study and
684 review of the literature. *Eur J Neurol* 25: 348-355, 2018.

685 **Devigili G, Tugnoli V, Penza P, Camozzi F, Lombardi R, Melli G, Broglio L, Granieri E,**
686 **and Lauria G.** The diagnostic criteria for small fibre neuropathy: from symptoms to
687 neuropathology. *Brain* 131: 1912-1925, 2008.

688 **Estacion M, Han C, Choi JS, Hoeijmakers JG, Lauria G, Drenth JP, Gerrits MM, Dib-Hajj**
689 **SD, Faber CG, Merkies IS, and Waxman SG.** Intra- and interfamily phenotypic diversity in
690 pain syndromes associated with a gain-of-function variant of Nav1.7. *Mol Pain* 7: 92, 2011.

691 **Estacion M, Vohra BP, Liu S, Hoeijmakers J, Faber CG, Merkies IS, Lauria G, Black JA,**
692 **and Waxman SG.** Ca²⁺ toxicity due to reverse Na⁺/Ca²⁺ exchange contributes to
693 degeneration of neurites of DRG neurons induced by a neuropathy-associated Nav1.7
694 mutation. *J Neurophysiol* 114: 1554-1564, 2015.

695 **Faber CG, Hoeijmakers JG, Ahn HS, Cheng X, Han C, Choi JS, Estacion M, Lauria G,**
696 **Vanhoutte EK, Gerrits MM, Dib-Hajj S, Drenth JP, Waxman SG, and Merkies IS.** Gain of
697 function Nav1.7 mutations in idiopathic small fiber neuropathy. *Annals of neurology* 71:
698 26-39, 2012.

699 **Filous AR, and Silver J.** Neurite Outgrowth Assay. *Bio Protoc* 6: 2016.

700 **Fritz CO, Morris PE and Richler JJ.** Effect Size Estimates: Current Use, Calculations, and
701 Interpretation *Journal of Experimental Psychology; General.* 141: 2-18, 2012.

702 **Geng X, Elmadhoun O, Peng C, Ji X, Hafeez A, Liu Z, Du H, Rafols JA, and Ding Y.** Ethanol
703 and normobaric oxygen: novel approach in modulating pyruvate dehydrogenase complex
704 after severe transient and permanent ischemic stroke. *Stroke* 46: 492-499, 2015.

705 **Gibbons CH, Wang N, and Freeman R.** Capsaicin induces degeneration of cutaneous
706 autonomic nerve fibers. *Annals of neurology* 68: 888-898, 2010.

707 **Guemes M, Rahman SA, and Hussain K.** What is a normal blood glucose? *Arch Dis Child*
708 101: 569-574, 2016.

709 **Han C, Hoeijmakers JG, Ahn HS, Zhao P, Shah P, Lauria G, Gerrits MM, te Morsche RH,**
710 **Dib-Hajj SD, Drenth JP, Faber CG, Merkies IS, and Waxman SG.** Nav1.7-related small

711 fiber neuropathy: impaired slow-inactivation and DRG neuron hyperexcitability. *Neurology*
712 78: 1635-1643, 2012a.

713 **Han C, Hoeijmakers JG, Liu S, Gerrits MM, te Morsche RH, Lauria G, Dib-Hajj SD,**
714 **Drenth JP, Faber CG, Merkies IS, and Waxman SG.** Functional profiles of SCN9A variants
715 in dorsal root ganglion neurons and superior cervical ganglion neurons correlate with
716 autonomic symptoms in small fibre neuropathy. *Brain* 135: 2613-2628, 2012b.

717 **Han SE, Boland RA, Krishnan AV, Vucic S, Lin CS, and Kiernan MC.** Changes in human
718 sensory axonal excitability induced by an ischaemic insult. *Clin Neurophysiol* 119: 2054-
719 2063, 2008.

720 **Hoeijmakers JG, Faber CG, Lauria G, Merkies IS, and Waxman SG.** Small-fibre
721 neuropathies--advances in diagnosis, pathophysiology and management. *Nat Rev Neurol* 8:
722 369-379, 2012a.

723 **Hoeijmakers JG, Faber CG, Lauria G, Merkies IS, and Waxman SG.** Small-fibre
724 neuropathies—advances in diagnosis, pathophysiology and management. *Nature Reviews*
725 *Neurology* 8: 369, 2012b.

726 **Hoeijmakers JG, Han C, Merkies IS, Macala LJ, Lauria G, Gerrits MM, Dib-Hajj SD, Faber**
727 **CG, and Waxman SG.** Small nerve fibres, small hands and small feet: a new syndrome of
728 pain, dysautonomia and acromesomelia in a kindred with a novel NaV1.7 mutation. *Brain*
729 135: 345-358, 2012c.

730 **Imamura H, Nhat KP, Togawa H, Saito K, Iino R, Kato-Yamada Y, Nagai T, and Noji H.**
731 Visualization of ATP levels inside single living cells with fluorescence resonance energy
732 transfer-based genetically encoded indicators. *Proc Natl Acad Sci U S A* 106: 15651-15656,
733 2009.

734 **Izumi Y, and Zorumski CF.** Neuroprotective effects of pyruvate following NMDA-mediated
735 excitotoxic insults in hippocampal slices. *Neurosci Lett* 478: 131-135, 2010.

736 **Kiernan MC, and Bostock H.** Effects of membrane polarization and ischaemia on the
737 excitability properties of human motor axons. *Brain* 123 Pt 12: 2542-2551, 2000.

738 **Kitay BM, McCormack R, Wang Y, Tsoulfas P, and Zhai RG.** Mislocalization of neuronal
739 mitochondria reveals regulation of Wallerian degeneration and NMNAT/WLD(S)-mediated
740 axon protection independent of axonal mitochondria. *Hum Mol Genet* 22: 1601-1614, 2013.

741 **Kitayama H, Miura Y, Ando Y, Hoshino S, Ishizaka Y, and Koyanagi Y.** Human
742 Immunodeficiency Virus Type 1 Vpr Inhibits Axonal Outgrowth through Induction of
743 Mitochondrial Dysfunction. *Journal of Virology* 82: 2528, 2008.

744 **Kokotis P, Schmelz M, Kostouros E, Karandreas N, and Dimopoulos MA.** Oxaliplatin-
745 Induced Neuropathy: A Long-Term Clinical and Neurophysiologic Follow-Up Study. *Clin*
746 *Colorectal Cancer* 15: e133-140, 2016.

747 **Lacomis D.** Small-fiber neuropathy. *Muscle Nerve* 26: 173-188, 2002.

748 **Lark DS, Torres MJ, Lin CT, Ryan TE, Anderson EJ, and Neufer PD.** Direct real-time
749 quantification of mitochondrial oxidative phosphorylation efficiency in permeabilized
750 skeletal muscle myofibers. *Am J Physiol Cell Physiol* 311: C239-245, 2016.

751 **Lauria G, Cazzato D, Porretta-Serapiglia C, Casanova-Molla J, Taiana M, Penza P,**
752 **Lombardi R, Faber CG, and Merkies IS.** Morphometry of dermal nerve fibers in human
753 skin. *Neurology* 77: 242-249, 2011.

754 **Lenhard, W. and Lenhard, A.** Calculation of Effect Sizes. Retrieved
755 from: https://www.psychometrica.de/effect_size.html. Dettelbach (Germany):
756 Psychometrica., 2016.

757 **Lehmann HC, Chen W, Borzan J, Mankowski JL, and Hoke A.** Mitochondrial dysfunction
758 in distal axons contributes to human immunodeficiency virus sensory neuropathy. *Annals of*
759 *neurology* 69: 100-110, 2011.

760 **Marunaka Y.** Effects of internal Na and external K concentrations on Na/K coupling of Na,K-
 761 pump in frog skeletal muscle. *J Membr Biol* 101: 19-31, 1988.

762 **Nasu S, Misawa S, Nakaseko C, Shibuya K, Iose S, Sekiguchi Y, Mitsuma S, Ohmori S,**
 763 **Iwai Y, Beppu M, Shimizu N, Ohwada C, Takeda Y, Fujimaki Y, and Kuwabara S.**
 764 Bortezomib-induced neuropathy: axonal membrane depolarization precedes development
 765 of neuropathy. *Clin Neurophysiol* 125: 381-387, 2014.

766 **Natera-Naranjo O, Kar AN, Aschrafi A, Gervasi NM, Macgibeny MA, Gioio AE, and**
 767 **Kaplan BB.** Local translation of ATP synthase subunit 9 mRNA alters ATP levels and the
 768 production of ROS in the axon. *Molecular and Cellular Neuroscience* 49: 263-270, 2012.

769 **Palmgren MG, and Nissen P.** P-Type ATPases. *Annual Review of Biophysics* 40: 243-266,
 770 2011.

771 **Pathak D, Shields LY, Mendelsohn BA, Haddad D, Lin W, Gerencser AA, Kim H, Brand**
 772 **MD, Edwards RH, and Nakamura K.** The role of mitochondrially derived ATP in synaptic
 773 vesicle recycling. *J Biol Chem* 290: 22325-22336, 2015.

774 **Peeling J, Sutherland G, Brown RA, and Curry S.** Protective effect of dichloroacetate in a
 775 rat model of forebrain ischemia. *Neurosci Lett* 208: 21-24, 1996.

776 **Pellerin L, Pellegrini G, Bittar PG, Charnay Y, Bouras C, Martin JL, Stella N, and**
 777 **Magistretti PJ.** Evidence supporting the existence of an activity-dependent astrocyte-
 778 neuron lactate shuttle. *Dev Neurosci* 20: 291-299, 1998.

779 **Persson AK, Black JA, Gasser A, Cheng X, Fischer TZ, and Waxman SG.** Sodium-calcium
 780 exchanger and multiple sodium channel isoforms in intra-epidermal nerve terminals. *Mol*
 781 *Pain* 6: 84, 2010.

782 **Persson AK, Hoeijmakers JGJ, Estacion M, Black JA, and Waxman SG.** Sodium Channels,
 783 Mitochondria, and Axonal Degeneration in Peripheral Neuropathy. *Trends Mol Med* 22: 377-
 784 390, 2016.

785 **Persson AK, Kim I, Zhao P, Estacion M, Black JA, and Waxman SG.** Sodium channels
 786 contribute to degeneration of dorsal root ganglion neurites induced by mitochondrial
 787 dysfunction in an in vitro model of axonal injury. *J Neurosci* 33: 19250-19261, 2013a.

788 **Persson AK, Liu S, Faber CG, Merkies IS, Black JA, and Waxman SG.** Neuropathy-
 789 associated Nav1.7 variant I228M impairs integrity of dorsal root ganglion neuron axons.
 790 *Annals of neurology* 73: 140-145, 2013b.

791 **Polydefkis M, Yiannoutsos CT, Cohen BA, Hollander H, Schifitto G, Clifford DB,**
 792 **Simpson DM, Katzenstein D, Shriver S, Hauer P, Brown A, Haidich AB, Moo L, and**
 793 **McArthur JC.** Reduced intraepidermal nerve fiber density in HIV-associated sensory
 794 neuropathy. *Neurology* 58: 115-119, 2002.

795 **Press C, and Milbrandt J.** Nmnat Delays Axonal Degeneration Caused by Mitochondrial and
 796 Oxidative Stress. *The Journal of Neuroscience* 28: 4861, 2008.

797 **Rolyan H, Liu S, Hoeijmakers JG, Faber CG, Merkies IS, Lauria G, Black JA, and Waxman**
 798 **SG.** A painful neuropathy-associated Nav1.7 mutant leads to time-dependent degeneration
 799 of small-diameter axons associated with intracellular Ca²⁺ dysregulation and decrease in
 800 ATP levels. *Mol Pain* 12: 2016.

801 **Rossignol R, Gilkerson R, Aggeler R, Yamagata K, Remington SJ, and Capaldi RA.**
 802 Energy Substrate Modulates Mitochondrial Structure and Oxidative Capacity in Cancer Cells.
 803 *Cancer Research* 64: 985, 2004.

804 **Rueda CB, Llorente-Folch I, Amigo I, Contreras L, González-Sánchez P, Martínez-**
 805 **Valero P, Juaristi I, Pardo B, del Arco A, and Satrustegui J.** Ca²⁺ regulation of
 806 mitochondrial function in neurons. *Biochimica et Biophysica Acta (BBA) - Bioenergetics* 1837:
 807 1617-1624, 2014.

808 **Smith AG, Ramachandran P, Tripp S, and Singleton JR.** Epidermal nerve innervation in
809 impaired glucose tolerance and diabetes-associated neuropathy. *Neurology* 57: 1701-1704,
810 2001.

811 **So PW, and Fuller BJ.** Enhanced energy metabolism during cold hypoxic organ
812 preservation: studies on rat liver after pyruvate supplementation. *Cryobiology* 46: 295-300,
813 2003.

814 **Sokoloff L.** Energetics of Functional Activation in Neural Tissues. *Neurochemical Research*
815 24: 321-329, 1999.

816 **Takeuchi H, Mizuno T, Zhang G, Wang J, Kawanokuchi J, Kuno R, and Suzumura A.**
817 Neuritic beading induced by activated microglia is an early feature of neuronal dysfunction
818 toward neuronal death by inhibition of mitochondrial respiration and axonal transport. *J*
819 *Biol Chem* 280: 10444-10454, 2005.

820 **Tanaka T, Nagashima K, Inagaki N, Kioka H, Takashima S, Fukuoka H, Noji H,**
821 **Kakizuka A, and Imamura H.** Glucose-stimulated single pancreatic islets sustain increased
822 cytosolic ATP levels during initial Ca²⁺ influx and subsequent Ca²⁺ oscillations. *J Biol Chem*
823 289: 2205-2216, 2014.

824 **Tanaka Y, Yano H, Ogasawara S, Yoshioka S-i, Imamura H, Okamoto K, and Tsuneoka**
825 **M.** Mild Glucose Starvation Induces KDM2A-Mediated H3K36me2 Demethylation through
826 AMPK To Reduce rRNA Transcription and Cell Proliferation. *Molecular and Cellular Biology*
827 35: 4170-4184, 2015.

828 **Tantama M, Martinez-Francois JR, Mongeon R, and Yellen G.** Imaging energy status in
829 live cells with a fluorescent biosensor of the intracellular ATP-to-ADP ratio. *Nat Commun* 4:
830 2550, 2013.

831 **Verze L, Paraninfo A, Ramieri G, Viglietti-Panzica C, and Panzica GC.**
832 Immunocytochemical evidence of plasticity in the nervous structures of the rat lower lip.
833 *Cell Tissue Res* 297: 203-211, 1999.

834 **Wang P, Chen M, Yang Z, Yu T, Zhu J, Zhou L, Lin J, Fang X, Huang Z, Jiang L, and Tang W.**
835 Activation of Pyruvate Dehydrogenase Activity by Dichloroacetate Improves Survival and
836 Neurologic Outcomes After Cardiac Arrest in Rats. *Shock* 49: 704-711, 2018.

837 **Wendt, H. W.** Dealing with a common problem in social science: a simplified rank-biserial
838 coefficient of correlation based on the *U* statistic. *European Journal of Social Psychology*. 2:
839 463-465, 1972.

840 **Westermann B.** Bioenergetic role of mitochondrial fusion and fission. *Biochimica et*
841 *Biophysica Acta (BBA) - Bioenergetics* 1817: 1833-1838, 2012.

842 **Youle RJ, and van der Bliek AM.** Mitochondrial fission, fusion, and stress. *Science (New*
843 *York, NY)* 337: 1062-1065, 2012.

844 **Zeng J, Yang GY, Ying W, Kelly M, Hirai K, James TL, Swanson RA, and Litt L.** Pyruvate
845 improves recovery after PARP-1-associated energy failure induced by oxidative stress in
846 neonatal rat cerebrocortical slices. *J Cereb Blood Flow Metab* 27: 304-315, 2007.

847

848

849

850 **Figure 1. DRG neurons expressing I228M, a gain-of-function mutant of Nav1.7,**
851 **display reduced neurite length *in vitro***

852 Mouse DRG neurons were isolated from 6-8 week old mice and sister cultures,
853 prepared at the same time from the same animal by the same operator, were
854 electroporated with the plasmid encoding wild-type Nav1.7 or the mutant channel
855 along with RFP. After the electroporation, cells were plated on the coverslips coated
856 with laminin and cultured for 7 days. The resulting cultures were imaged and their
857 total lengths per cell were assessed as described in Methods.

858 A. Large-field montage image of WT-expressing DRG culture, consisting of 7X7
859 field views. Dotted lines distinguish individual field-of-view. Scale bar, 1000μm

860 B. Enlarged field view image of individual neurons transfected Nav1.7 WT

861 C. Large-field montage image of I228M-expressing DRG culture, consisting of
862 7X7 field views. Dotted lines distinguish individual field-of-view. Scale bar, 1000μm

863 D. Enlarged field view image of individual neurons transfected Nav1.7 I228M

864 Quantification of total length per cell of WT and I228M neurons calculated from
865 large-field images and the average for each condition. Each data point represents
866 total neurite length per cell from each culture. Dotted line indicates mean value of
867 control. Data are normalized to WT values and presented as mean ± standard
868 deviation. Mean of WT (n = 34 cultures from 8 animals) and I228M (34 cultures
869 from 8 animals) are 1.000 ± 0.1870 and 0.7966 ± 0.1755 , respectively. MD (WT -
870 I228M) is 0.2034 ± 0.04398 . CI is 0.1155 to 0.2912. I228M culture displays a 20 %
871 decrease in neurite lengths with **** $p < 0.0001$, (nested t test).

872

873 **Figure 2. DRG neurons expressing I228M display a significant reduction in**
874 **neurite length at reduced glucose concentrations.**

875 Mouse DRG cultures expressing the indicated channels were prepared as described
876 in Methods. The cultures were then maintained in the culture media containing 25,
877 5.7, or 2.7mM glucose for 7 days. The resulting cultures were imaged, and their
878 neurite lengths were assessed as described in Methods. Data are normalized to the
879 neurite length values of 25mM glucose cultures and presented as mean ± standard
880 deviation. Dotted line indicates mean value of control.

881 A. WT neurons show a similar extent of neurite outgrowth in all the range of
882 glucose concentrations (25mM: 1 ± 0.3057 , n = 19 cultures from 5 animals ; 5.7mM:
883 1.1346 ± 0.3452 , n = 19 cultures from 5 animals; 2.7mM: 1.1569 ± 0.3740 , n = 11
884 cultures from 3 animals).

885 B. I228M neurons display neurite length reductions in the low glucose
886 conditions, compared to 25mM glucose (25mM: 1 ± 0.2902 , n = 20 cultures from 5
887 animals; 5.7mM: 0.9036 ± 0.1966 , n = 20 cultures from 5 animals; 2.7mM: $0.7471 \pm$
888 0.2218 from n = 12 cultures from 3 animals).

889 I228M-transfected culture displays a 25 % reduction in neurite lengths at 2.7mM
890 glucose, compared to the culture at 25mM glucose (** $p = 0.0120$, nested one way
891 ANOVA followed by Dunnett's multiple comparisons test. MD (25mM-2.7mM) is
892 0.2529 ± 0.08847 . CI is 0.04879 to 0.4570. In contrast to the mutant culture, WT
893 culture did not show reduced neuritic growths in the low glucose concentrations
894 (NS, not significant, nested one way ANOVA followed by Dunnett's multiple
895 comparisons test).

896
897 **Figure 3. [ATP]i levels are decreased in DRG neurons expressing I228M.**

898 Steady-state levels of ATP were measured from cultured DRG neurons using a FRET-
899 based ATP indicator approach. ATeam, an ATP FRET probe was expressed in mouse
900 DRG neurons along with the indicated channels. 7 days after culturing, FRET signals
901 of transfected neurons were measured in the absence or the presence of rotenone as
902 described in Methods.

903 A. Representative FRET images of ATeam-expressing DRG neurons

904 B. I228M-expressing neurons exhibit a reduced FRET signal, compared to WT
905 neurons (WT: 3.738 ± 0.612 from $n = 218$ cells; I228M: 3.542 ± 0.770 from $n = 121$
906 cells, $p = 0.0042$, Mann-Whitney test). Each data point represents a FRET value from
907 each cell. Dotted line indicates mean value of control.

908 C. Representative FRET images of ATeam-expressing DRG neurons treated with
909 rotenone

910 I228M-expressing neurons exhibit a markedly reduced FRET signal, compared to
911 WT neurons in the presence of rotenone (WT: 3.408 ± 0.800 from $n = 250$ cells;
912 I228M: 3.031 ± 1.042 from $n = 325$ cells, $p > 0.0001$ Mann-Whitney test). Each data
913 point represents a FRET value from each cell. Dotted line indicates mean value of
914 control.

915
916 **Figure 4. DRG neurons expressing I228M display a rapid ATP reduction,**
917 **compared to WT neurons in response to membrane depolarization.**

918 ATP kinetics of DRG neurons were assessed in response to depolarization as
919 described in Methods. Mouse DRG neurons transfected with ATeam along with
920 Nav1.7 WT or I228M and FRET changes were monitored after depolarization with
921 50mM KCl.

922 A. Representative time-lapse images of ratiometric FRET change of DRG
923 neurons expressing the indicated channels. Scale bar, 50 μm .

924 B. Traces represent means of WT neurons ($n=8$) and I228M neurons ($n=7$).
925 Error bars represent standard deviations.

926 C. Quantification of FRET changes of DRG neurons after membrane
927 depolarization by 50mM [K⁺], Area under the curve (AUC) was calculated and the

928 difference between the groups was analyzed (WT: -222.6 ± 56.2 , $n=8$; I228M: -
 929 291.8 ± 25.8 , $n=7$). Dotted line indicates mean value of control.
 930 D. Representative time-lapse images of ratiometric FRET change of DRG
 931 neurites expressing the indicated channels. Scale bar, 10 μm .
 932 E. Traces represent means of WT neurites ($n=12$) and I228M neurites ($n=12$).
 933 Error bars represent standard deviations.
 934 Quantification of FRET changes of DRG neurites after membrane depolarization by
 935 50mM $[\text{K}^+]$, Area under the curve (AUC) was calculated and the difference between
 936 the groups was analyzed (WT: -450.9 ± 169.3 , $n=12$; I228M: -1085 ± 281.2 , $n=12$).
 937 Dotted line indicates mean value of control.

938
 939 **Figure 5. Increasing pyruvate availability fails to increase the neurite length of**
 940 **I228M neurons.**

941 I228M neurons were treated as indicated, in order to increase pyruvate availability
 942 for mitochondria and assess the effects of those treatments in the neuritic growth.
 943 Mouse DRG neurons were isolated from 6-8 weeks old mice and electroporated with
 944 the plasmid encoding wild type Nav1.7 or the mutant channel along with RFP. After
 945 electroporation, the cells were plated on the coverslips coated with laminin and
 946 cultured for 7 days in the indicated treatments.

947 A. Carbohydrate energy metabolism and its feedback regulation
 948 Using pyruvate, mitochondria produce more ATP through TCA cycle and oxidative
 949 phosphorylation (OXPHOS) than glycolysis and lactate fermentation do. Glucose
 950 negatively regulate mitochondrial TCA and OXPHOS *via* pyruvate dehydrogenase
 951 kinase.

952 B. The effect of pyruvate supplementation in neurite lengths. Each data point
 953 represents total neurite length per cell from each culture. Dotted line indicates mean
 954 value of control. Data are normalized to the value of I228M-control (without
 955 pyruvate) and presented as mean $\pm$ standard deviation (I228M-Control: $1.067 \pm$
 956 0.413 , $n = 17$ cultures from 6 animals; I228M-pyruvate: 1.284 ± 0.704 , $n = 15$
 957 cultures from 6 animals). Difference between means is not significant ($p = 0.2027$,
 958 nested t test). MD (Control-Pyruvate) is -0.4249 ± 0.3117 . CI is -1.120 to 0.2696 .
 959 The effect of DCA treatment in neurite lengths. Each data point represents total
 960 neurite length per cell from each culture. Dotted line indicates mean value of control.
 961 Data are normalized to the value of I228M-control (without DCA treatment) and
 962 presented as mean $\pm$ standard deviation (I228M-Control: 0.9981 ± 0.301 , $n = 12$
 963 cultures from 3 animals ; I228M-DCA: 1.021 ± 0.387 , $n = 10$ cultures from 3 animals).
 964 Difference between means is not significant ($p = 0.8827$, nested t test). MD (Control-
 965 DCA) is -0.02322 ± 0.1551 . CI is -0.3490 to 0.3026 .

966

Figure 6. I228M-expressing neurons exhibit alterations in mitochondrial distribution and morphology.

Mitochondria were genetically labeled by transfecting Mito-DsRed into mouse DRG neurons expressing the indicated human Nav1.7 plasmids. Mitochondria with red fluorescence were imaged and counted in transfected neurites, as described in Methods.

A. A representative image of neuritic mitochondria of DRG neurons expressing WT. Scale bar, 50 μ m.

B. A representative image of neuritic mitochondria of DRG neurons expressing I228M. Scale bar, 50 μ m.

C. Mitochondrial density of WT- and I228M-expressing neurites. Dotted line indicates mean value of control. Each data point represents an individual neurite. Data are normalized to neurite length and presented as mean $\pm$ standard deviation. The graph represents mean of mitochondrial numbers per μ m. (WT: 0.1449 ± 0.0229 , n=39 neurites; I228M: 0.1323 ± 0.0046610298 , n=41 neurites, $*p = 0.0371$, unpaired t test). MD (WT-I228M) is 0.01266 ± 0.005967 . CI is -0.02453 to -0.00078.

D. Mitochondrial size of WT- and I228M-expressing neurites. Dotted line indicates mean value of control. Each data point represents an individual mitochondria. Data are presented as mean $\pm$ standard deviation. The graph represents the mean of pixel numbers (WT: 112 ± 171.59 , n=1453 mitochondria; I228M: 90.47 ± 130.01 , n=1014 mitochondria, $***p = 0.007$, Mann-Whitney test). I228M neurons display a modest but significant reduction in mitochondrial density and size in neurites, compare to WT neurons.

Figure 7. Dexpramipexole promotes neurite growth of I228M-expressing neurons.

I228M neurons were treated with 2 μ M dexpramipexole for 7 days and the neurite lengths were compared to those of the untreated group.

A. A representative montaged image of I228M-expressing DRG culture.

B. A field view image of the montaged image shown in A


C. A representative montaged image of I228M-expressing DRG culture in a coverslip.

D. A field view image of the montaged image shown in C


E. Quantification of total length per cell of I228M-control and I228M-treatment group. Dotted line indicates mean value of control. Each data point represents total neurite length per cell from each culture. Data are normalized to neurite control value and presented as mean $\pm$ standard deviation (I228M-Control: 1 ± 0.0974 , n = 12 cultures from 3 animals; I228M-2 μ M dexpramipexole: 1.287 ± 0.08403 , n = 12 cultures from 3 animals). MD (DEX-Control) is 0.2875 ± 0.09296 . CI is -0.009469 to

1006 0.4803. Dex-treated I228M culture displays a 29 % increase in neurite lengths with
1007 *** $p = 0.0053$, (nested t test).
1008 F. Quantification of total length per cell of WT-control and WT-treatment group.
1009 Dotted line indicates mean value of control. Each data point represents total neurite
1010 length per cell from each culture. Data are normalized to neurite control value and
1011 presented as mean $\pm$ standard deviation (WT-Control: 1 ± 0.0828 from $n = 10$
1012 cultures from 3 animals; WT-2 μ M dexpramipexole: 1.034 ± 0.0839 , $n = 10$ cultures
1013 from 3 animals). MD (DEX-Control) is -0.03392 ± 0.1179 . CI is -0.2816 to 0.2138 .
1014 Dex-treated WT culture did not displays any significant change in neurite lengths. (p
1015 $= 0.7768$, Nested t test).
1016

Figure 1, Lee *et al.*



E






A**B**


Figure 3, Lee *et al.*




A



D



E



F




Figure 5, Lee *et al.*




Figure 6, Lee *et al.*




Figure 7, Lee *et al.*

